{"id":50853,"date":"2025-12-15T21:40:36","date_gmt":"2025-12-15T13:40:36","guid":{"rendered":"https:\/\/flcube.com\/?p=50853"},"modified":"2025-12-15T21:40:38","modified_gmt":"2025-12-15T13:40:38","slug":"kyinno-biotechnology-closes-rmb-250m-series-b-for-bispecific-antibody-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50853","title":{"rendered":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline"},"content":{"rendered":"\n<p><strong>Kyinno Biotechnology<\/strong>, a China\u2011based biotech company, announced the completion of its <strong>Series B financing round<\/strong> raising close to <strong>RMB 250 million<\/strong>. The round was <strong>co\u2011led by BioTrack Capital<\/strong>, the <strong>Beijing Medical and Health Industry Investment Fund<\/strong>, and <strong>E-Town Capital<\/strong>, with participation from <strong>China Everbright Limited (0165.HK)<\/strong>, <strong>Jinyi Fuxin<\/strong>, <strong>Renai Capital<\/strong>, <strong>Yizhuang Investment<\/strong>, and existing shareholder <strong>Yuanhui Chuangyi<\/strong>, which increased its stake.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Financing Round<\/strong><\/td><td>Series B<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>Close to RMB 250 million<\/td><\/tr><tr><td><strong>Co\u2011Leads<\/strong><\/td><td>BioTrack Capital, Beijing Medical and Health Industry Investment Fund, E-Town Capital<\/td><\/tr><tr><td><strong>Participants<\/strong><\/td><td>China Everbright Limited (HKG: 0165), Jinyi Fuxin, Renai Capital, Yizhuang Investment<\/td><\/tr><tr><td><strong>Existing Investor<\/strong><\/td><td>Yuanhui Chuangyi (increased investment)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-use-of-proceeds\">Use of Proceeds<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Use Category<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Pipeline Advancement<\/strong><\/td><td>Accelerate collaborative development and clinical advancement of First\u2011in\u2011Class and Best\u2011in\u2011Class bispecific\/multi\u2011specific antibodies<\/td><\/tr><tr><td><strong>Technology Platforms<\/strong><\/td><td>Strengthen proprietary &#8220;Common Light Chain&#8221; and &#8220;Nanobody&#8221; technology platforms<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>Actively expand global business development partnerships<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Common Light Chain<\/strong><\/td><td>Proprietary technology enabling efficient development of bispecific and multi\u2011specific antibodies<\/td><\/tr><tr><td><strong>Nanobody<\/strong><\/td><td>Platform for generating nanobody\u2011based therapeutic candidates<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Kyinno:<\/strong> The financing validates its <strong>bispecific antibody platform<\/strong> and provides capital to advance a differentiated pipeline toward clinical milestones and potential global partnerships.<\/li>\n\n\n\n<li><strong>For Investors:<\/strong> Co\u2011leads include <strong>government\u2011backed funds<\/strong> (Beijing Medical, E\u2011Town), signaling policy support for innovative biotech, while private investors gain exposure to the <strong>high\u2011growth bispecific therapy market<\/strong>.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> China\u2019s bispecific antibody sector is projected to reach <strong>\u00a515\u202fbillion<\/strong> (\u2248\u202fUS$2.1\u202fB) by 2030; Kyinno\u2019s platform positions it as a <strong>competitive player<\/strong> in next\u2011generation immuno\u2011oncology and autoimmune therapies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Kyinno\u2019s pipeline advancement, platform development, and global partnership expansion. Actual results may differ due to clinical risks, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50854,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2010],"class_list":["post-50853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-kyinno-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50853\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline\" \/>\n<meta property=\"og:description\" content=\"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50853\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T13:40:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T13:40:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline\",\"datePublished\":\"2025-12-15T13:40:36+00:00\",\"dateModified\":\"2025-12-15T13:40:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853\"},\"wordCount\":313,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1510.webp\",\"keywords\":[\"KYinno Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50853#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50853\",\"name\":\"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1510.webp\",\"datePublished\":\"2025-12-15T13:40:36+00:00\",\"dateModified\":\"2025-12-15T13:40:38+00:00\",\"description\":\"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50853\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50853#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50853","og_locale":"en_US","og_type":"article","og_title":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline","og_description":"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.","og_url":"https:\/\/flcube.com\/?p=50853","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-15T13:40:36+00:00","article_modified_time":"2025-12-15T13:40:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50853#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50853"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline","datePublished":"2025-12-15T13:40:36+00:00","dateModified":"2025-12-15T13:40:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50853"},"wordCount":313,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50853#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","keywords":["KYinno Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50853#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50853","url":"https:\/\/flcube.com\/?p=50853","name":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50853#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50853#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","datePublished":"2025-12-15T13:40:36+00:00","dateModified":"2025-12-15T13:40:38+00:00","description":"Kyinno Biotechnology, a China\u2011based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co\u2011led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50853#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50853"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50853#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","width":1080,"height":608,"caption":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50853#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50853"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50853\/revisions"}],"predecessor-version":[{"id":50855,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50853\/revisions\/50855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50854"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}